Cargando…

Pharmacometric analyses to characterize the effect of CSL112 on apolipoprotein A‐I and cholesterol efflux capacity in acute myocardial infarction patients

AIMS: To characterize relationships between apolipoprotein A‐I (apoA‐I) exposure and cholesterol efflux capacity (CEC) and covariate effects following CSL112 (apoA‐I [human]) administration in an integrated population including acute myocardial infarction (AMI) patients. METHODS: A pharmacometric an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Bo, Duffy, Danielle, Tricoci, Pierluigi, Kastrissios, Helen, Pfister, Marc, Wright, Samuel D., Gille, Andreas, Tortorici, Michael A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247400/ https://www.ncbi.nlm.nih.gov/pubmed/33217027 http://dx.doi.org/10.1111/bcp.14666

Ejemplares similares

Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A‐I [Human]) to Enhance Cholesterol Efflux Capacity
por: Gille, Andreas, et al.
Publicado: (2018)

CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients
por: Gille, Andreas, et al.
Publicado: (2018)

Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity
por: Kingwell, Bronwyn A., et al.
Publicado: (2022)

Effect of CSL112 (apolipoprotein A‐I [human]) on cholesterol efflux capacity in Japanese subjects: Findings from a phase I study and a cross‐study comparison
por: Zheng, Bo, et al.
Publicado: (2022)

Correction to: Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity
Publicado: (2023)

Pharmacokinetics and Safety of CSL112 (Apolipoprotein A‐I [Human]) in Adults With Moderate Renal Impairment and Normal Renal Function
por: Tortorici, Michael A., et al.
Publicado: (2018)

Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study
por: Gurbel, Paul A., et al.
Publicado: (2018)

Enhanced HDL Functionality in Small HDL Species Produced Upon Remodeling of HDL by Reconstituted HDL, CSL112: Effects on Cholesterol Efflux, Anti-Inflammatory and Antioxidative Activity
por: Didichenko, Svetlana A., et al.
Publicado: (2016)

Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction
por: Korjian, Serge, et al.
Publicado: (2023)

Clinical Pharmacokinetics and Pharmacodynamics of CSL112
por: Ortega-Paz, Luis, et al.
Publicado: (2023)

Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial
por: Tricoci, Pierluigi, et al.
Publicado: (2015)

Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I)
por: Michael Gibson, C., et al.
Publicado: (2016)

Cholesterol efflux capacity assay using immobilized liposomes and apolipoprotein B-depleted serum
por: Sapa, Hima Rani
Publicado: (2019)

Guanosine effect on cholesterol efflux and apolipoprotein E expression in astrocytes
por: Ballerini, Patrizia, et al.
Publicado: (2006)

Apolipoprotein M promotes cholesterol uptake and efflux from mouse macrophages
por: Yao, Shuang, et al.
Publicado: (2021)

Cholesterol Efflux Capacity of Apolipoprotein A-I Varies with the Extent of Differentiation and Foam Cell Formation of THP-1 Cells
por: Yano, Kouji, et al.
Publicado: (2016)

Usefulness of apolipoprotein B-depleted serum in cholesterol efflux capacity assays using immobilized liposome-bound gel beads
por: Horiuchi, Yuna, et al.
Publicado: (2019)

Uremia alters HDL composition and cholesterol efflux capacity
por: Holzer, Michael, et al.
Publicado: (2012)

Cholesterol Efflux Capacity and Its Association With Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis
por: Lee, Jane J., et al.
Publicado: (2021)

Development and validation of novel automatable assay for cholesterol efflux capacity
por: Mutsuda, Yume, et al.
Publicado: (2023)

Relationship between HDL Cholesterol Efflux Capacity, Calcium Coronary Artery Content, and Antibodies against ApolipoproteinA-1 in Obese and Healthy Subjects
por: Vuilleumier, Nicolas, et al.
Publicado: (2019)

Caveolin-1-Mediated Apolipoprotein A-I Membrane Binding Sites Are Not Required for Cholesterol Efflux
por: Le Lay, Soazig, et al.
Publicado: (2011)

The negative effect of ANGPTL8 on HDL-mediated cholesterol efflux capacity
por: Luo, Mengdie, et al.
Publicado: (2018)

Lower than average HDL cholesterol efflux capacity in Lithuanian population
por: Kutkiene, Sandra, et al.
Publicado: (2019)

HDL cholesterol efflux capacity and lipid profile in patients with systemic sclerosis
por: Ferraz-Amaro, Iván, et al.
Publicado: (2021)

Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial
por: Metzinger, Mark P., et al.
Publicado: (2020)

Structural properties of apolipoprotein A-I mimetic peptides that promote ABCA1-dependent cholesterol efflux
por: Islam, Rafique M., et al.
Publicado: (2018)

Conformational flexibility of apolipoprotein A-I amino- and carboxy-termini is necessary for lipid binding but not cholesterol efflux
por: Bedi, Shimpi, et al.
Publicado: (2022)

Metaheuristics for pharmacometrics
por: Kim, Seongho, et al.
Publicado: (2021)

It’s Time to Reassess the High-Density Lipoprotein (HDL) Hypothesis: CSL112, a Novel Promising Reconstituted HDL Formulation
por: Marsche, Gunther
Publicado: (2015)

Fungal CSL transcription factors
por: Převorovský, Martin, et al.
Publicado: (2007)

Targeted cholesterol efflux
por: Fang, Longhou, et al.
Publicado: (2013)

Evaluation of machine learning methods for covariate data imputation in pharmacometrics
por: Bräm, Dominic Stefan, et al.
Publicado: (2022)

Extracellular lipid-free apolipoprotein E inhibits HCV replication and induces ABCG1-dependent cholesterol efflux
por: Crouchet, Emilie, et al.
Publicado: (2017)

Association of Cholesterol Efflux Capacity With Clinical Features of Metabolic Syndrome: Relevance to Atherosclerosis
por: Gall, Julie, et al.
Publicado: (2016)

Impact of Endothelial Lipase on Cholesterol Efflux Capacity of Serum and High-density Lipoprotein
por: Schilcher, Irene, et al.
Publicado: (2017)

ApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacity
por: Luo, Mengdie, et al.
Publicado: (2017)

Effects of pre-eclampsia on HDL-mediated cholesterol efflux capacity after pregnancy
por: Kockx, Maaike, et al.
Publicado: (2022)

Pharmacometrics and Machine Learning Partner to Advance Clinical Data Analysis
por: Koch, Gilbert, et al.
Publicado: (2020)

Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy
por: Tortorici, Michael A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tbgu7toj54bdu11vvuvfloegk1